Blood Transfusion - 2 2020 (March-April)
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET
Authors:  Giancarlo Castaman, Cristina Santoro, Antonio Coppola, Maria E. Mancuso, Rita C. Santoro, Sergio Bernardini, Francesco R. Pugliese, Riccardo Lubrano, Maria Golato, Armando Tripodi, Angiola Rocino, Elena Santagostino, on behalf of the ad hoc Working Group* (*Co-Authors listed in the Appendix 1)
Pages:  143-151
To cite this article:  Blood Transfus 2020; 18: 143-51
Doi:  10.2450/2019.0186-19
Published online:  18/10/2019

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. In addition, when surgery/invasive procedures are needed while on emicizumab, their management requires multidisciplinary competences and direct supervision by experts in the use of this agent. Given this, and in order to expand the current knowledge on the use of emicizumab and concomitant haemostatic agents, and reduce the risk of complications in this setting, the Italian Association of Haemophilia Centres (AICE) here provides guidance on the management of breakthrough bleeds and surgery in emergency situations in patients with haemophilia A and inhibitors on emicizumab prophylaxis. This paper has been shared with other National Scientific Societies involved in the field.
Keywords: haemophilia A, emicizumab, emergency, FVIII inhibitors, bypassing agents.
Full Text Download Back
Share this article: